Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7624MR)

This product GTTS-WQ7624MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7624MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8391MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ3278MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ15497MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ14548MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ9532MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ4602MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ6239MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW